Analysis by Test Type (Urine Analysis, Blood Tests, and Others); by Product Type {Instruments (Victor 2D Instrument, Auto DELFIA Immunoassay System, and Others), and Consumables}; and by End-User (Hospitals, Specialty Clinics, Diagnostic Centers, Research Centers, and Others) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2033
Buy Now
The global preeclampsia diagnostics market is estimated to garner a revenue of ~USD 4 Billion by the end of 2033 by growing at a CAGR of ~13% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~USD 1 Billion in the year 2022. The growth of the market is primarily attributed to the globally rising cases of preeclampsia. For instance, the worldwide occurrence of preeclampsia has reached nearly 5% of all pregnancies. Additionally, increasing sedentary lifestyle adoption is causing a rise in disease incidences. An increased risk of developing preeclampsia was linked to more sitting time each day. Further, chronic hypertension, obesity, diabetes, and kidney disease make pregnant women more vulnerable to this disease.
Preeclampsia, also defined as toxemia, is a rapidly complex condition marked by high blood pressure and an excess of protein in pregnant women's urine. It is a hypertensive disorder of pregnancy and a major cause of mortality, long-term frailty, and death in both the unborn baby and the mother. Preeclampsia is most prevalent after the 20th week of pregnancy. For instance, preeclampsia disease accounts for 2% to 9% of pregnancy-related complications, more than 51,000 maternal deaths globally. Also, Preeclampsia affects women more frequently in low- and middle-income nations since they have less access to high-quality healthcare. Therefore, there has been growing awareness among healthcare provider and pregnant women which is further estimated to boost the market growth.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~13% |
|
Base Year Market Size (2022) |
~ USD 1 Billion |
|
Forecast Year Market Size (2035) |
~ USD 4 Billion |
|
Regional Scope |
|
Growth Drivers
Increasing Prevalence of Hypertension in Pregnancy – High blood pressure is also known as hypertension that affects the body arteries by making heart to work harder to pump blood. Hypertension in pregnancy needs a regular monitoring to keep the track of raised blood pressure. Therefore, growing cases of hypertension in pregnancy is fueling up the growth of the preeclampsia diagnostics market. It is observed that, an estimated 4% to 11% of all pregnancies are complicated by hypertension in pregnancy.
Upsurge in the Occurrence of Placenta Previa – For instance, the issue of placenta previa is affecting nearly 1% to 4% of third-trimester pregnancies.
Rising Development Activities for New Tests to Detect Biomarkers Indicating Preeclampsia – As per a clinical study, in women with subclinical preeclampsia, gestational hypertension, essential hypertension, or moderate preeclampsia, a combination of CT-pro-ET1, sFlt-1, and systolic blood pressure formed sensitivity of 80% and precision of 90% for the development of severe preeclampsia within 1 week. Thus, ET-1 or its byproduct protein CT-pro-ET1 may be advantageous in disease prediction or treatment planning.
Escalation in Receiving Prenatal Care – As per the data provided by the World Bank, in 2019 88% of pregnant women received prenatal care across the globe.
Globally Increasing Healthcare Expenditure – According to the World Bank, in 2019, worldwide healthcare expenditure increased by 9.83%.
Challenges
The global preeclampsia diagnostics market is segmented and analyzed for demand and supply by test type into urine analysis, blood tests, and others. Out of these, the blood tests segment is anticipated to garner the largest market share over the forecast period owing to the accuracy of blood tests in efficiently detecting the biomarkers, and rising number of blood tests types which have been introducing in the market. For instance, in England, few newer blood tests were introduced to detect the preeclampsia under the guidance of related governmental bodies. DELFIA Xpress PLGF 1-2-3, Delfia Xpress sFlt-1/Xpress PLGF1-2-3 ratio, Elecsys immunoassay sFlt-1/PLGF ratio, and Triage PLGF Test are the four tests recommended in the guidelines in first half of 2022.
The global preeclampsia diagnostics market is also segmented and analyzed for demand and supply by end-user into hospitals, specialty clinics, diagnostic centers, research centers, and others. Amongst which, the hospitals segment is anticipated to garner the highest revenue by the end of 2033. The growth of the segment can be attributed to growing number of hospitals visit by pregnant women. Additionally, improved healthcare infrastructure is also estimated to boost the segment growth over the forecast period. Moreover, the establishment of hospitals is growing in developing region which is why the preference for hospital is growing.
Our in-depth analysis of the global preeclampsia diagnostics market includes the following segments:
|
By Test Type |
|
|
By Product Type |
|
|
By End-User |
|
The North American preeclampsia diagnostics market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2033, backed by the rising adoption of highly advanced products, growing awareness among people regarding the preeclampsia, upsurge in development of diagnostic imaging services, growing prevalence of pregnancy related disorders, and cumulative healthcare expenditure in the region. According to a clinical study, over the last 12 years, in the United States, the rate of high blood pressure-related diseases among pregnant women have more than doubled, rising from 38% per 1,000 live births in 2007 to 78% in 2019.
Further, the market in the Europe region is estimated to grow significantly by the end of 2033. The growth of this region can be attributed to growing pregnant women who are suffering from hypertension disorders. Also, rising government healthcare organization approvals for the detection of hypertension disorders in pregnancy may promote market expansion in Europe. Moreover, the pregnancy prevalence is also increasing which is also estimated to boost the diagnostics frequency in this region.
In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.
Ans: Increasing prevalence of hypertension in pregnancy, upsurge in the occurrence of placenta previa, and escalation in receiving prenatal care are some major factors driving the growth of the market.
Ans: The market is anticipated to attain a CAGR of ~13% over the forecast period, i.e., 2023 – 2035.
Ans: Lack of awareness about preeclampsia, very late detection of preeclampsia disorder, and unavailability of preeclampsia diagnostic products are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Ans: The major players in the market are F. Hoffmann-La Roche Ltd, PerkinElmer, Inc., Diabetomics, Inc., Thermo Fisher Scientific Holdings, Inc., Metabolomic Diagnostics, DRG Instruments GmbH, and others.
Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by test type, product type, end-user, and by region.
Ans: The blood tests segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Submit Your Request For Proposal (RFP)
